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A brainstorming and consensus meeting organized by the German Cancer Aid focused on modern treatment of
prostate cancer and promising innovative techniques and research areas. Besides optimization of screening algorithms,
molecular-based stratification and individually tailored treatment regimens will be the future of multimodal prostate
cancer management. Effective interdisciplinary structures, including biobanking and data collection mechanisms are
the basis for such developments.Introduction
Treatment of patients with prostate cancer has improved
over the last decades, based on the understanding of
tumor biology, molecular characteristics of tumors, im-
provement in surgical techniques as well as innovations
in radiation oncology. Today, treatment of prostate can-
cer is an interdisciplinary task involving several treating
disciplines and in some situations competing treatment
options. Every modality is associated with distinct risk-
benefit profiles, and intensive patient counseling as well
as clinical and imaging findings are the basis for treat-
ment decisions.
Decades ago treatment usually was limited to radical sur-
gical resection of the prostate or simple conformal radiation
therapy being associated with side effects, such as in-
continence, bowel dysfunction and impotence, among
others. Nowadays, improved anatomic nerve-sparing sur-
gical approaches, development of robot-assisted surgery
and intensity modulated radiation therapy have improved* Correspondence: Stephanie.Combs@tum.de
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domized studies have shown that adjuvant radiotherapy
can increase progression-free and overall survival. In
general, radiotherapy has become a valid treatment al-
ternative in patients with prostate cancer, and with de-
finitive treatments applied with high-end radiotherapy
long-term curation can be achieved.
As individualized treatments are emerging, evaluation
of molecular markers in tumor tissue, epigenetic factors
or other risk constellations become more relevant and
are focus of several research strategies. Biobanking struc-
tures are essential to expand knowledge in this regard.
In the future, this novel information may help stratify
patients for certain treatment modalities, treatment
intensification or prevent subgroups of patients from
over-treatment.
To bundle all these relevant data and innovative con-
cepts, a consensus meeting in 2013 funded by the German
Cancer Aid was held bringing together experts in the
relevant fields for prostate cancer treatment and to lay
the basis for future structured research concepts. The
aim of the present manuscript is to summarize state-of-the
art treatment, recent research results as well as prospective
strategies for the future discussed in this framework. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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linary prostate cancer researchers in the fields of medicine,
biology, physics as well as health care management.
State of the Art Urology
Prostate cancer remains the most common malignancy
and the second most common cause of cancer related
death in men (Surveillance Epidemiology and End Results:
SEER). Since the introduction of blood based PSA testing
in the 1970’s the prostate cancer incidence significantly
increased until the 1990’s but remained stable over the
last ten years (SEER). State of the art therapies currently
lead to 5- and 10-year survival rates of 100% and 98%
respectively (SEER). The effect of PSA screening on the
high survival rates is still discussed controversially
between two leading studies in the United States (PLCO)
and Europe (ERSPC). Both studies have enrolled large
number of men (PLCO: 77.000/ERSPC:162.000) and have
reported follow-up of 13 and 11 years respectively until
today. While the PLCO study does not show any signifi-
cant reduction in prostate cancer related mortality in the
screening arm, the ERSPC study does show reduction in
mortality of up to 29% [1]. Consensus on the data of
ERSPC show clearly that beneficial effects from screening
only become visible after a period of several years of
follow up, as reported in the New England Journal of
Medicine in 2012. Critics are especially on the PLCO
study (high contamination of screened men outside the
trial within the control arm), which limit the quality of
the conclusions, which can be drawn from the study.
But also the ERSPC study concludes despite the mortality
reduction that more data especially on adverse effects of
screening and cost effectiveness have to be acquired to
make a final recommendation [1]. Several publications fol-
lowing the report of the two studies came to the same
conclusion that individual decisions for screening have to
be made between the patient and his physician [2-4]. This
consensus opinion was strongly supported especially by
the coordinators of the ERSPC study. In general, “the
patient has to come first” in an individualized decision
process for screening and treatment.
Despite the high 5- and 10 year survival rates prostate
cancer mortality is estimated to be 29.000 cases with
238.000 newly diagnosed cases for 2013 (SEER). To iden-
tify and treat those patients, who have a tumor, which will
cause severe symptoms or will be lethal is the persisting
challenge in the daily routine of urologists and oncolo-
gists. At the same time unnecessary invasive diagnostic
procedures or treatments have to be minimized [1].
Once a tumor has been diagnosed and validated in
histological biopsies several treatment options especially
for the organ-confined tumor are available. To prospect-
ively compare the different regimens available, prospective
multicenter trials such as the German PREFERE Study(NCT01717677) are required. In this four arm preference
based study, surgery (radical prostatectomy), radiation (ex-
ternal beam or permanent seed implantation) and active
surveillance will be compared in terms of effectiveness
and side effects in a multicenter randomized trial includ-
ing over 7000 men.
The surgical technique has been refined to the extent
of robot assisted minimally invasive systems (DaVinci),
which deliver 3D vision to the surgeon and level out
even minimal shaking of his hands [5]. Open and min-
imally invasive nerve sparing operations are standard of
care, if the tumor grade permits it [6]. Simultaneously,
active surveillance has gained more attention due to in-
creasing rates of overtreatment in the face of the large
numbers of low risk tumors detected through PSA-
testing. The ERSPC study estimated the percentage of
over-diagnosed men in the age group 55–74 to be as
high as 50% [1]. Active surveillance requires continuous
follow-up to measure PSA kinetics and to re-evaluate
tumor progression by invasive needle biopsies. Increas-
ing Gleason scores, increase tumor volume and rapidly
increasing PSA values are widely accepted trigger points
for treatment. Controversy of PSA measurement and
needle biopsy frequency is still ongoing, since follow-up
time in active surveillance clinical trials is still too short.
Moreover, the promising potential of multiparametric
magnetic resonance imaging (MRI) of the prostate to
non-invasively monitor tumors over time is gaining ex-
ponential attention.
Focus in the future has to be on additional diagnostic
parameters to clearly identify low risk tumors, which will
not need treatment and separate them from high risk tu-
mors, which do need aggressive treatment. It is believed
that the heterogeneous outcome of prostate tumors is
based on different tumor subtypes, which could be de-
fined by certain molecular properties. Currently, several
national and international institutions have set up large
efforts to further delineate the molecular heterogeneity
of prostate tumors.
To “bridge the gap from mind to market” multidisciplin-
ary efforts are needed that include clinicians as well as
academia and industry. Molecular screening of human
samples, target validation in in-vitro and in-vivo systems,
protection of intellectual property and optimization of
candidate compounds through biotech spin-offs for initi-
ation of clinical trials within the same institution can lead
to successful novel therapies. Among others, the clusterin
inhibitor Custirsen (OGX-011) has been developed in
such a way at the Vancouver Prostate Centre and is cur-
rently evaluated in phase III clinical trials.
Data collection at clinical high volume centers can lead
to multiparameter assessment of clinical and molecular
data. This provides a basis to successfully implement risk
assessment scores to sub classify prostate tumors. Tissue
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be screened using various ‘-omics’ approaches to identify
novel marker signatures for different tumor subtypes.
Thereby surgical samples are being translated into clinically
applicable diagnostic tools. An additional level of tumor
alterations called ‘epigenetics’ is currently being explored
in one of Germany’s largest collaborative research centers
MEDEP (medical epigenetics) at Freiburg University
Hospital. The collaboration follows a multidisciplinary
approach to define epigenetic diagnostic and therapeutic
tools for prostate cancer.
State of the Art Radiation Oncology
Radiotherapy has been established as a clear treatment
alternative in patients with prostate cancer. This is due
to the significant developments over the last decades,
continuously increasing precision of dose delivery to the
tumor while sparing normal tissue and thus reducing
treatment-related side effects.
The biggest step was the development of 3D-CT-based
treatment planning, which is considered the treatment
standard today. With this, dose conformality to the pros-
tate and radiation doses could be increased. An early
study evaluated this possible dose escalation in patients
with prostate cancer, and could show that higher doses
increase biological progression-free survival independ-
ently from tumor stage and risk stratification, while side
effects where rather reduced compared to older treat-
ment techniques [7]; this was confirmed also in long-
term follow-up. The improved biochemical control of
higher doses at 74–80 Gy compared to <70 Gy have
been confirmed by several groups [8-11]. Subsequent im-
provements included further modulation of photon beams,
such as Intensity Modulated Radiotherapy (IMRT; [12,13]).
Here, each individually formed radiation field is in itself
inhomogeneous, adapting the dose within the field config-
uration to anatomical requirements. IMRT significantly
helped decrease toxicity when applying high-dose radio-
therapy to the prostate; even with doses above 80 Gy only
moderate side effect, e.g. to the rectum, are observed
[11,14-16]. For intermediate-risk and high-risk patients,
however, 5-year biochemical relapse free survival remains
between 30-45%, thus further treatment optimization is
required. Recently, further dose escalation trials beyond
80 Gy have been conducted, and even ultra-high doses of
86.4 Gy are being evaluated. Spratt et al., reported only re-
cently long-term follow-up data after a median of 5.5 years,
with 7-year biochemical relapse free survival of 98.8%,
85.6% and 67.9% for low- intermediate and high-risk pa-
tients [17]. However, for most approaches real long-term
follow-up still remains to be awaited.
For further improvement of the therapeutic window,
modern radiation machines are coupled with imaging,
such as in-room CT-scanners, or radiation and imagingin one machine. Daily imaging prior to treatment is pos-
sible, correcting potential positioning errors of the pa-
tient. Currently, adaption of dose distribution not only
to interfractional movement, but also to intra-fractional
changes is possible. This means, dose distribution can
follow movement and deformation of organs at risk
(OAR), of the target volumes or target organs (Adaptive
Radiotherapy, ART). Research is currently establishing
technical advancements such as gating (radiation is on
when the target is within a certain range of the move-
ment amplitude) or tracking (radiation follows move-
ment of the target) [13]. Combinations of radiation and
imaging in terms of Image Guided Radiotherapy (IGRT)
have lead to further increase of dose in prostate cancer
treatment, thus further increasing outcome [12,18,19].
With these technical developments, also local dose in-
crease to e.g. positive lymph nodes in patients with pel-
vic nodal disease can be targeted precisely, e.g. based on
PSMA-PET-Imaging.
The dose-limiting OAR in the treatment of prostate
cancer is the anterior rectal wall, lying directly poster-
iorly to the prostate. Thus steep dose gradients to the
rectum are essential. One means to spare the rectum
from dose is application of a sterile gel between the
prostate and the rectum, providing several millimeters of
space to produce a dose gradient [20]. Such gel applica-
tions together with highly advanced treatment techniques
contribute beneficially to the risk to benefit profile.
Novel treatment modalities in radiotherapy may lead
to further improvements. Particle therapy offers physical
as well as biological benefits, the latter for high-LET
(Linear Energy Transfer) particles. When entering the
patient particles deposit very low energy, followed by
steep dose deposition in the so called Bragg Peak. The
depth of the Bragg Peak is energy-dependent. Thereafter
a sharp-fall-off spares tissue behind the target volume
additionally. Due to these physical properties the integral
dose to the patient can be reduced, and the dose con-
formality can be enhanced. This is about comparable for
protons and carbon ions, while carbon ions are high-
LET particles associated with a higher relative biological
effectiveness. Due to the biological properties of prostate
cancer tissue with a high α/β value, there is substantial
rationale for the use of the carbon beam. Additionally,
increase of daily dose and reduction of overall treatment
time (hypofractionation) is feasible, which from a radio-
biological perspective seems to be favorable for prostate
cancer tissue. To date, no randomized trial on the real
value of particle therapy is available. One study in the USA
has compared standard treatment to a dose-escalation
using a proton boost in the experimental arm; this study
has shown increase in outcome for the high-dose arm,
however, such dose escalation is today potentially possible
using IMRT/IGRT approaches not available at the time of
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study has only compared high-dose versus low-dose.
However, the data remain a randomized trial comparing
proton dose escalation, and further studies must still
show that outcome and toxicity are comparable with
photon dose escalation [16]. Future study designs must
aim at comparison of these highly advanced techniques
in patients with prostate cancer [21].
Imaging and staging
While over years CT-based diagnostics as well as ultra-
sonography were considered the imaging standard in
prostate cancer, multiparametric MRI as well as novel
molecular imaging based on PET or SPECT imaging
contribute significantly to differential staging, and enable
individualized treatment strategies.
Currently, the basis for staging of high risk disease re-
mains to be contrast-enhanced CT-imaging to describe
the extent of nodal involvement in the pelvis, as well as
to identify bony lesions. Staging should be completed by
bone szintigraphy to rule out bone metastases. Emerging
functional imaging, including diffusion-weighted MRI
and dynamic contrast-enhanced MRI, MR-spectroscopy,
lymph-node specific contract agents as well as PET-
imaging using novel tracers can provide novel insights
and potential for treatment improvement. Improved
nodal characterization together with size and location of
high-risk sub-regions or identification of prostate-cancer
affected regions within the prostate provide great poten-
tial for the future.
Over recent years, PET-Imaging with 11C-choline has
emerged as a promising diagnostic tool for patients with
prostate cancer. It has been shown that 11C-choline has
a high sensitivity in prostate cancer patients, and clinical
evaluations have shown a better diagnostic accuracy for
choline PET in comparison with other conventional im-
aging modalities; early detection of recurrences may lead
early treatment and thus improved overall outcome.
Lately, PET/CT and hybrid PET/MRI with Gallium 68
prostate-specific membrane antigen (PSMA) ligands have
shown promising results with further improved sensitivity
as compared to choline tracers [22,23] Based on such
molecular imaging, not only early and accurate diagno-
ses become possible, but also targeted treatment can
be implemented: endoradiotherapy and radiation therapy
with integrated boost concept to PET-positive lesions for
primary definitive treatment, or localized small-volume
radiotherapy to PET-positive lesions are worth investigat-
ing and are currently evaluated within prospective clinical
trials.
Biobanking and epidemiology
In order to develop novel diagnostic or therapeutic tar-
gets their validation in large numbers of tissue samplesis necessary. As already demonstrated in the previous
topics, tissue derived data can be very rewarding but they
require an enormous degree of planning, maintenance
and funding resources in order to provide high quality
biological material and data over a long period of time.
Not only the sample collection, histologic validation,
storage, inventarisation and the retrieving algorithm
are important but also the connection to clinical data
and its continuous updating [24]. An example of the
power of large-scale tissue microarray (TMA) analysis
was presented: a collaborative group a researchers from
Heidelberg and Hamburg compared genomic alter-
ations in 11 early onset tumors from younger patients
to 7 late onset tumors from elderly patients and discov-
ered a preference of androgen driven structural genomic
alterations (e.g. TMPRSS-ERG fusion) in the early onset
tumors. These initial findings were validated using TMA
technique representing over 10.000 patients’ tissue sam-
ples and confirmed the original findings [25]. There was
strong consensus that high quality tissue biobanking is of
high interest and importance and should be seen as an in-
vestment in the future of improving disease diagnostics
and treatment in the framework of all cancer centers.
Apart from novel targets on the molecular level clas-
sical family history also provides valuable information in
risk assessment of prostate cancer: Fallah and colleagues
incorporated the degree of relationship (first degree or
second degree relative) and the co-occurrence of pros-
tate cancer, breast cancer or esophageal cancer into a
score (PCRAM: prostate cancer risk assessment model;
[26]) to optimize the starting point for prostate cancer
screening.
Patient stratification and biomarkers
The introduction of large-scale next generation sequen-
cing techniques into cancer research opened a whole
new research field. The results however suggest that the
heterogeneity among prostate tumors is far higher than
anticipated before [27]. Analysis of single structural al-
terations might not be sufficient to characterize a whole
tumor. Multilayer analysis of structural genomic alter-
ations, mutations, gene-fusion events, methylation status
and the resulting gene expression will have to be ana-
lyzed in individual patients to determine optimal risk
adapted treatment. Several groups have followed re-
search in this field: Rubin et al. [28] followed this ap-
proach recently and deep sequenced 57 prostate cancer
genomes together with benign control tissue. They dis-
covered that several structural genomic alterations were
derived from a single event. This mechanism established
a large number of structural alterations in a coordinated
fashion in cancer tissue caused by only a few catastrophic
events. They termed this mechanism chromoplexy.
The model of chromoplexy will help to understand the
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cer. The use of next generation sequencing techniques
can help in the future to stratify prostate cancer. Rubin
stated, that despite the huge amount of sequencing data
provided by international and national genome projects
such as the International Cancer Genome Consortium
(ICGC) or The Cancer Genome Atlas (TCGA) it is es-
sential to filter out the meaningful alterations and put
them into a context of cellular processes, which can be
targeted [25].
The question, if disrupted signaling pathways may in-
fluence or even cause genomic instability is in focus for
several research groups: in Heidelberg Duensing and col-
leagues have discovered a number of factors, which dis-
rupt the integrity of mitosis leading to aneuploidy such
as the fibroblast growth factor 2 (FGF2), centrosomal
protein 57 (CEP57) and polo-like kinase 4 (PLK4) [29,30].
Duensing and his team hope to use theses molecules as
novel biomarkers in early stages of cancer diagnostics.
Another approach follows the search for novel bio-
markers however on the epigenetic level. The teams
around Büttner and Schüle et al. found that the levels
of lysine specific demethylase 1 (LSD1) predict the clinical
behavior of prostate cancer [31]. Further unraveling of the
mechanism of action of this enzyme and its co-factors
might open novel diagnostic and therapeutic options. Ra-
ther than sequencing the whole genome epigenomic ana-
lysis sequences only those DNA sections, which are
occupied by DNA modifying enzymes such as e.g. LSD1.
None of the above projects would have been possible
without the analytical power of bioinformatics. Manke
and colleagues co-developed a computational tool to pre-
dict the DNA binding affinity for DNA binding molecules
such as transcription factors to better understand and pre-
dict the presence of combinations of transcription factors
at any given gene regulatory sequence [32].
Biostatistics is a key player in all tissue- and molecular-
based analyses: novel programs and accessible tools to
visualize multilayer data for scientific use, e.g. by circus
plots, are currently under investigation. Large-scale com-
putational analysis recently revealed that younger patients
have smaller tumors but higher percentage of driver muta-
tions compared to tumors in elderly patients [25]. The im-
plications of genetic counseling based on such data will
have to be discussed with great care in the future.
The vast technical possibilities opened up by next
generation sequencing technologies, high volume tis-
sue biobanking resources and computational analysis
power offers promising novel pathways to pursue diag-
nostic and therapeutic strategies.
Systemic treatment
For advanced disease, several options in terms of systemic
treatment are available. This includes androgen deprivationtherapy, chemotherapy, and novel molecular targets [33,34].
The oldest player in this context is certainly adrogen
deprivation therapy: Continuous androgen deprivation is
often continued indefinitely regardless of additional ther-
apies, however at some point may not lead to a con-
tinuous tumor control. In addition, some therapies to
be offered additionally have demonstrated survival and
quality-of-life benefits: This includes abiraterone acetate
and prednisone, enzalutamide, or Radium-223 in patients
with bone metastases. For chemotherapeutic agents, doce-
taxel and prednisone are often administered. In this field
several prospective clinical trials are under evaluation, es-
pecially with focus on the question when to offer andro-
gen deprivation therapy (early or later during the disease
course), and when to switch to other systemic options.
Prospective trials
In the era of personalized medicine prospective clinical
trials are required to identify the role of molecular markers,
specific tumor and normal tissue characteristics or epigen-
etic factors on the course of prostate cancer. To achieve
this, large multi-center collaborative structures including
biospecimens should be planned and conducted. For
these, intelligent trial design on smaller patient subgroups
as well as large prospective clinical trials are required to
compare existing treatment alternatives. The role of bio-
logically stratified treatment decisions must be validated
for individual patient cohorts.
Initiatives such as the German PREFERE study for low-
and early intermediate-risk prostate cancer patients, as
well as cohort studies and prospective registers on active
surveillance and wait-and-see strategies further character-
izing the natural course of prostate cancer are currently
ongoing, and will provide scientific results in the near fu-
ture. Lacking to date are real comparisons of surgery and
radiation therapy, for intermediate risk or high-risk tu-
mors. For such trials, not only commitment of the surgical
and radiation community are necessary, but also patient
willingness to undergo randomization procedures. Often
patients have a strong personal preference and therefore
feel uncomfortable undergoing randomization. However,
extensive information about the treatment characteristics
as well as the specific side effects, benefits or advantages
of the different treatment alternatives may help develop
such trial concepts. Within single disciplines, direct com-
parison of alternative modalities or concepts are also
warranted: To date, no study has shown superiority robot-
assisted surgery compared to open surgery performed by a
highly experienced surgical team. In radiation oncology,
long-term data of very high-dose radiation therapy coupled
with IGRT are being awaited, and the most recent contro-
versy about the value of particle therapy for the treatment
of prostate cancer requires a direct comparative prospective
trial of particle therapy with high-end photon treatment.
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The two-day workshop funded and organized by the
German Cancer Aid provided an informative platform
for exchange of novel data and innovative treatment
concepts. Current state-of-the-art treatment recommen-
dations in the different disciplines were presented and
discussed. A strong consensus was set on the future of
individualized treatment, taking into account molecular
signatures of tumor tissue for stratification. In the era of
personalized medicine, each medical discipline should
tailor their treatment to the individual needs and prefer-
ences of the single patient.
Competing interests
The authors declare no competing interests.
Authors’ contributions
SEC and MS collected the data and wrote the manuscript. JD, GF, BH, MH, RS
and JPZ critically read the manuscript and added information. All authors
reviewed and agreed on the final version of the manuscript.
Author details
1Technische Universität München (TUM), Klinikum rechts der Isar,
Department of Radiation Oncology, Ismaninger Straße 2, 81675 München,
Germany. 2Bundesverband Prostatakrebs Selbsthilfe e.V., Alte Straße 4, 30989
Gehrden 3, Germany. 3Department of Urology, University Hospital
Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
4Universitätsklinikum Freiburg, Urologie, Hugstetter Strasse 55, 79106
Freiburg, Germany. 5Department of Radiation Oncology, University Hospital
of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Received: 21 January 2014 Accepted: 29 September 2014
References
1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V,
Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A,
Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der
Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M,
Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators: Prostate-cancer
mortality at 11 years of follow-up. N Engl J Med 2012, 366:981–990.
2. McNaughton-Collins MF, Barry MJ: One man at a time–resolving the PSA
controversy. N Engl J Med 2011, 365:1951–1953.
3. Brett AS, Ablin RJ: Prostate-cancer screening–what the U.S. Preventive
Services Task Force left out. N Engl J Med 2011, 365:1949–1951.
4. Schroder FH: Stratifying risk–the U.S. Preventive Services Task Force and
prostate-cancer screening. N EnglJ Med 2011, 365:1953–1955.
5. Carlucci JR, Nabizada-Pace F, Samadi DB: Robot-assisted laparoscopic radical
prostatectomy: technique and outcomes of 700 cases. Int J Biomed Sci 2009,
5:201–208.
6. Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M,
Guazzoni G, Menon M, Mottrie A, Patel VR, Van der Poel H, Rosen RC, Tewari AK,
Wilson TG, Zattoni F, Montorsi F: Systematic review and meta-analysis of
studies reporting potency rates after robot-assisted radical prostatectomy.
Eur Urol 2012, 62:418–430.
7. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK,
Pollack A: Long-term results of the M. D. Anderson randomized
dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys
2008, 70:67–74.
8. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA,
Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM,
Scrase CD, Stephens RJ, Syndikus I, Parmar MK, RT01 collaborators:
Escalated-dose versus standard-dose conformal radiotherapy in
prostate cancer: first results from the MRC RT01 randomised
controlled trial. Lancet Oncol 2007, 8:475–487.
9. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF,
Bonfrer JM, Incrocci L, Lebesque JV: Dose–response in radiotherapy for
localized prostate cancer: results of the Dutch multicenter randomizedphase III trial comparing 68 Gy of radiotherapy with 78 Gy. J ClinOncol 2006,
24:1990–1996.
10. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA,
Starkschall G, Rosen I: Preliminary results of a randomized radiotherapy
dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.
J Clin Oncol 2000, 18:3904–3911.
11. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU:
Comparison of conventional-dose vs high-dose conformal radiation
therapy in clinically localized adenocarcinoma of the prostate: a
randomized controlled trial. JAMA 2005, 294:1233–1239.
12. Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK,
Zhang X: A comprehensive comparison of IMRT and VMAT plan quality for
prostate cancer treatment. Int J Radiat Oncol Biol Phys 2012, 83:1169–1178.
13. Combs SE, Schulz-Ertner D, Herfarth KK, Krempien R, Debus J: [Advances in
radio-oncology. From precision radiotherapy with photons to ion therapy
with protons and carbon ions]. Chirurg 2006, 77:1126–1132.
14. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA,
Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ: Randomized trial
comparing conventional-dose with high-dose conformal radiation therapy
in early-stage adenocarcinoma of the prostate: long-term results from
proton radiation oncology group/american college of radiology 95–09.
J Clin Oncol 2010, 28:1106–1111.
15. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA,
Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL:
Long-term multi-institutional analysis of stage T1-T2 prostate cancer
treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003,
57:915–928.
16. Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL:
Patient-reported long-term outcomes after conventional and high-dose
combined proton and photon radiation for early prostate cancer.
JAMA 2010, 303:1046–1053.
17. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ: Long-term
survival and toxicity in patients treated with high-dose intensity modulated
radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys
2013, 85:686–692.
18. Tucker SL, Zhang M, Dong L, Mohan R, Kuban D, Thames HD: Cluster
model analysis of late rectal bleeding after IMRT of prostate cancer: a
case–control study. Int J Radiat Oncol Biol Phys 2006, 64:1255–1264.
19. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Hunt M,
Wolfe T, Venkatraman ES, Jackson A, Skwarchuk M, Leibel SA: Clinical
experience with intensity modulated radiation therapy (IMRT) in prostate
cancer. Radiother Oncol 2000, 55:241–249.
20. Song DY, Herfarth KK, Uhl M, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R,
Weber DC, Miralbell R, Deweese TL, Ford EC: A Multi-institutional Clinical
Trial of Rectal Dose Reduction via Injected Polyethylene-Glycol Hydrogel
During Intensity Modulated Radiation Therapy for Prostate Cancer: Analysis
of Dosimetric Outcomes. Int J Radiat Oncol Biol Phys 2013, 87(1):81–87.
21. Combs SE, Djosanjh M, Pötter R, Orrechia R, Haberer T, Durante M, Fossati P,
Parodi K, Balosso J, Amaldi U, Baumann M, Debus J: Towards clinical
evidence in particle therapy: ENLIGHT, PARTNER. ULICE and beyond.
J Radiat Res 2013, 54(Suppl 1):i6–i12.
22. Roethke MC, Kuru TH, Afshar-Oromieh A, Schlemmer HP, Hadaschik BA,
Fenchel M: Hybrid Positron Emission Tomography-Magnetic Resonance
Imaging with Gallium 68 Prostate-specific Membrane Antigen Tracer: A
Next Step for Imaging of Recurrent Prostate Cancer-Preliminary Results.
Eur Urol 2013, 64:862–864.
23. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG,
Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U: Comparison of
PET imaging with a Ga-labelled PSMA ligand and F-choline-based PET/CT
for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging
2013, 41(1):11–20.
24. Huber J, Herpel E, Jakobi H, Hadaschik BA, Pahernik S, Hohenfellner M: Two
decades’ experience with a prospective biobank for urologic oncology:
research, clinical care, and the patients’ view. Urol Oncol 2013, 31(7):990–996.
25. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S,
Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM,
Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C,
Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T,
Galal R, et al: Integrative genomic analyses reveal an androgen-driven somatic
alteration landscape in early-onset prostate cancer. Cancer Cell 2013,
23:159–170.
Combs et al. Radiation Oncology 2014, 9:224 Page 7 of 7
http://www.ro-journal.com/content/9/1/22426. Roudgari H, Hemminki K, Brandt A, Sundquist J, Fallah M: Prostate cancer risk
assessment model: a scoring model based on the Swedish Family-Cancer
Database. J Med Genet 2012, 49:345–352.
27. Boyd LK, Mao X, Lu YJ: The complexity of prostate cancer: genomic
alterations and heterogeneity. Nat Rev Urol 2012, 9:652–664.
28. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K,
Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A,
Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC,
Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G,
Voet D, Ramos AH, Winckler W, et al: Punctuated evolution of prostate cancer
genomes. Cell 2013, 153:666–677.
29. Cuevas R, Korzeniewski N, Tolstov Y, Hohenfellner M, Duensing S: FGF-2
disrupts mitotic stability in prostate cancer through the intracellular
trafficking protein CEP57. Cancer Res 2013, 73:1400–1410.
30. Korzeniewski N, Hohenfellner M, Duensing S: CAND1 promotes PLK4-mediated
centriole overduplication and is frequently disrupted in prostate cancer.
Neoplasia 2012, 14:799–806.
31. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G,
Bastian PJ, Ellinger J, Metzger E, Schüle R, Buettner R: Androgen receptor
coactivators lysine-specific histone demethylase 1 and four and a half
LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer
Res 2006, 66:11341–11347.
32. Thomas-Chollier M, Hufton A, Heinig M, O'Keeffe S, Masri NE, Roider HG,
Manke T, Vingron M: Transcription factor binding predictions using TRAP
for the analysis of ChIP-seq data and regulatory SNPs. Nat Protoc 2011,
6:1860–1869.
33. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K,
Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J,
Winquist E, Bennett CL, Wootton T, Rumble RB, Dusetzina SB, Virgo KS:
Systemic Therapy in Men With Metastatic Castration-Resistant Prostate
Cancer: American Society of Clinical Oncology and Cancer Care Ontario
Clinical Practice Guideline. J Clin Oncol 2014, 32(30):3436–48.
34. Loblaw DA, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK,
Lyman GH, Basch E, Americal Society of Clinical Oncology Clinical
Practice Guidelines: American Society of Clinical Oncology Clinical
Practice Guidelines: formal systematic review-based consensus
methodology. J Clin Oncol 2012, 30:3136–3140.
doi:10.1186/s13014-014-0224-4
Cite this article as: Combs et al.: Current state of the art, multimodality
research and future visions for the treatment of patients with prostate
cancer: consensus results from “Challenges and Chances in Prostate
Cancer Research Meeting 2013”. Radiation Oncology 2014 9:224.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
